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Objective: Overexpression of protooncogenes and cellular growth
factor receptors have been implicated in the development of oste-
osarcomas. HER2 (human epidermal growth factor receptor 2) is
a 185-Kd transmembrane glycoprotein receptor that is the product
of the c-erbB-2 protooncogene. It is structurally homologous to
EGFR  (epidermal growth factor receptor). Recent studies  have
reported that 42%-45% of OS overexpress HER2 and that overex-
pression of HER2 in OS correlates with a worse event-free survival,
and a poor histologic response to induction chemotherapy. This
has stimulated interest in investigating the use of anti-HER2 mon-
oclonal antibodies in treatment protocols as part of initial or sal-
vage  chemotherapy  regimens  for  poor  prognosis  patients.
Expression of EGFR in OS has not been thoroughly investigated
although its overexpression by other tumor types has been corre-
lated with  a poor  prognosis. The  purpose  of  this  study was to
examine the expression of HER2 and EGFR in OS and to deter-
mine  the  relationship  between  overexpression  and  survival,
response  to  induction  chemotherapy,  local  and systemic  recur-
rence, and various other potential prognostic factors.
Methods: Archival  paraffin  embedded  tissue  from  32  patients
with the diagnosis of high-grade OS were stained for HER2 (Her-
cep Test- DAKO Corp) and EGFR (Mouse Anti-EGFR, ZYMED
LABS)  via  standard immunohistochemical  techniques.  Cellular
membrane staining was graded 0 to 3+ according to intensity. The
receptors were considered to be overexpressed if grade 2 or 3 stain-
ing was present.
Results: HER2 was not expressed in any specimen.  (All speci-
mens demonstrated grade 0 staining for HER2.) EGFR was over-
expressed in five (16%) specimens. Overexpression of EGFR did
not correlate with prognosis or with any significant prognostic var-
iables.
Conclusion: HER2 and EGFR do not demonstrate significant nor
consistent overexpression by OS cells. They are unlikely to repre-
sent  important  prognostic  variables.  Therapy  with  anti-HER2
antibody or IMC-C225  (anti-EGFR ab) may not be beneficial.
Further investigation is required.
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Objective: Synovial sarcoma is a high-grade soft tissue sarcoma
characterized by a bi-phasic morphology and is associated with a
poor prognosis. Most synovial sarcoma posses a specific chromo-
somal translocation (t(X:18) p11.2;q11.2). Surgery and adjuvant
chemotherapy has improved the outcome of local disease, how-
ever,  management  of  distant  metastasis  remains  problematic.
Accordingly there is a need for alternate adjuvant therapies. The c-
erbB2  proto-oncogene  encodes  the  human  epidermal  growth
factor  receptor  2  (HER-2/neu),  a  membrane  bound  tyrosine
kinase, overexpressed in a number of carcinomas.
Methods: Archival  cases  of  synovial  sarcomas  (n=16)  were
assessed for HER-2/neu oncogene expression by standard immu-
nohistochemical techniques.
Results: Eleven of the cases (68%) demonstrated the membra-
nous staining reminiscent of over expression in breast carcinomas.
To  validate  the  immunohistochemistry  results,  RT-PCR  using
archival material was performed and demonstrated the presence of
mRNA for c-erbB2 in 10 of 13 (72%) of cases.
Conclusion: These results demonstrate c-erbB2 expression in the
majority of synovial sarcoma and suggest treatment with recom-
binant humanized anti-HER2 monoclonal antibodies may repre-
sent an appropriate alternate therapy for patients who have failed
conventional therapy.
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Objective: Because of the  difference in clinical  management of
enchondromas and central grade I chondrosarcomas it is impor-
tant to make a correct preoperative diagnosis. The purpose of this
study was to investigate the diagnostic value of histologic parame-
ters in differentiating enchondroma and central grade I chondrosa-
rcoma.
Methods: Cytologic  and  tissue-architectural  features  of  57
patients, with 20 enchondromas and 37 central grade I chondrosa-
rcomas, were assessed. During the microscopically assessment, the
observer was aware of the localization of the tumor, the age of the
patient and clinical symptoms (like swelling, pain or fracture). A
final diagnosis was used as gold standard obtained after at least 10
years of follow-up and assessed in a multidisciplinary meeting with
full clinical, radiological and pathology data available. Tumors of
the digits and toes were excluded because of their specific (benign)
clinical  behavior,  despite  aggressive  morphologic  features.  The
chi-square  test,  classification  trees  and  logistic  regression  were
used to assess the discriminating power of the individual parame-
ters and to find an optimal set of parameters.
Results: Entrapment, cellularity, nuclear polymorphism and dis-
tribution of cells were the individual parameters with the most dis-
criminating  strength  (p<0.001).  The  combination  of  high
cellularity,  present  host  bone  entrapment,  open  chromatin,
mucoid matrix quality >= 20% and an age above 45 years gives a
perfect prediction. Also, the matrix quality proved to be a strong
discriminating feature. A statistical classification tree shows that if
mucoid matrix degeneration is more then 20% or entrapment is
present (or both of them), the tumor will be almost certain malig-
nant and otherwise almost certain benign.
Conclusion: The  application  of  a  combination  of  5  histologic
parameters  showed  a  optimal  ability  to  differentiate  between
enchondromas  and  central  grade  I  chondrosarcomas.  With  a
simple  classification  tree, based on 2  parameters, 54  of the  57
(94.7%) cases were assessed correct (sensitivity 95% and specifi-
city 95%). Using this diagnostic approach combined with an tai-
lored radiological assessment will lead to an optimal therapeutic
classification.S30 CTOS  abstracts
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Objective: Malignant  fibrous  histiocytoma  (MFH) represents  a
heterogeneous soft tissue sarcoma entity. We have compared dif-
ferent methods to determine immunohistochemical (ICH) stain-
ing in whole-tissue sections, evaluated the tissue-array technique
and assessed ICH heterogeneity using the proliferation marker Ki-
67.
Methods: The techniques were evaluated in 47 tumor blocks from
11 MFH. Whole-tissue sections were assessed using two reference
methods  (counting 400  cells  along  a  line  or  counting  10  high
power fields, x40). Tissue-array utilized multiple 0.6 mm tumor
biopsies.
Results: The whole-tissue methods gave Ki-67 expression levels
of 13% and 11%, respectively and the tissue-array technique cor-
related well with the whole-tissue ICH with average 8.6% higher
Ki-67 expression in the array-sections. ICH heterogeneity gave a
median standard deviation (SD) of 2.3% within the tumor blocks
and of 2.5% between the blocks from the same tumor.
Conclusion: We  conclude  that  the  tissue-array  method  yields
good quality ICH staining and expression levels for Ki-67 compa-
rable to whole-tissue staining in MFH. Because of tumor hetero-
geneity several tumor blocks should ideally be studied and due to
loss of biopsies in the array-process multiple  biopsies should be
taken. The feasibility  of  tissue-array  offers  new possibilities  for
ICH studies using multiple markers in large tumor series.
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Objective: Canine osteosarcoma is  a naturally occurring tumor
homologous to their human tumors in morphology and behavior.
Consequently the canine neoplasm is a useful model to test new
disease modifying agents. Recently, the treatment of other mesen-
chymal tumors using anti-tyrosine kinase drugs, especially drugs
targeted against the PDGF family has been proposed. The PDGF
family consists of 3 dimeric proteins, which act as ligands for the 2
receptors (PDGFR-a and PDGFR-b) with tyrosine kinase activity.
The dimers are formed by subunits A and B can bind as the het-
erodimer or the homodimers. PDGF-B is similar to proto-onco-
gene c-sis, which is involved in the malignant transformation of
fibroblast cultures. The a receptor is stimulated by all three iso-
forms of the ligand, whereas the b-receptor only binds the PDGF-
B homodimer with high affinity.
Methods: In this study, the expression of the PDGF family mem-
bers in 84 canine osteosarcomas (73 primary and 11 pulmonary
metastatic neoplasms) was examined using a tissue microarray and
immunohistochemistry.
Results: PDGF-A and PDGF-B  expression was detected in 43
(51%)  and  8  tumors  (9.5%)  respectively.  66  tumors  (78.5%)
expressed PDGFR-a and 52 tumors (61.9%) expressed PDGFR-
b respectively. Concomitant expression  of the  ligand (PDGF-A
and PDGF-B) and receptor (PDGFR-a) was seen in all of the met-
astatic lesions, whereas primary neoplastic lesions demonstrated
likewise concomitant expression in 27 lesions (36%).
Conclusion: These results suggest autocrine and paracrine stimu-
lation of osteosarcoma cells  in metastatic  lesions.  Furthermore,
these results suggest metastatic  osteosarcoma may be a possible
target for anti-PDGFR drugs.